Alkermes kept by Merrill Lynch at buy

Alkermes Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy rating with a price target on the stock of $19 per share following news that the FDA has extended the review of Vivitrex - a once-monthly shot to treat alcoholism in development with Cephalon Inc. - to Dec. 30. Alkermes shares Wednesday were down $1.67, or 8.94%, at $17.00 on volume of 2,871,855 shares versus the three-month running average of 1,150,260 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.